Morgan Stanley
DSGN icon

Morgan Stanley’s Design Therapeutics DSGN Stock Holding History

Morgan Stanley’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.99M Sell
656,565
-45,741
-7% -$463K ﹤0.01% 3871
2025
Q4 		$6.59M Buy
702,306
+526,315
+299% +$4.12M ﹤0.01% 3969
2025
Q3 		$1.33M Sell
175,991
-37,559
-18% -$188K ﹤0.01% 5021
2025
Q2 		$720K Sell
213,550
-34,328
-14% -$128K ﹤0.01% 5275
2025
Q1 		$957K Sell
247,878
-98,305
-28% -$469K ﹤0.01% 5020
2024
Q4 		$2.14M Sell
346,183
-82,615
-19% -$478K ﹤0.01% 4649
2024
Q3 		$2.31M Buy
428,798
+39,361
+10% +$185K ﹤0.01% 4546
2024
Q2 		$1.3M Sell
389,437
-88,655
-19% -$345K ﹤0.01% 4813
2024
Q1 		$1.93M Sell
478,092
-608,870
-56% -$1.63M ﹤0.01% 4611
2023
Q4 		$2.88M Buy
1,086,962
+726,704
+202% +$1.66M ﹤0.01% 4737
2023
Q3 		$850K Buy
360,258
+169,490
+89% +$791K ﹤0.01% 4893
2023
Q2 		$1.2M Buy
190,768
+121,391
+175% +$743K ﹤0.01% 4727
2023
Q1 		$400K Buy
69,377
+27,953
+67% +$209K ﹤0.01% 5379
2022
Q4 		$425K Sell
41,424
-17,511
-30% -$237K ﹤0.01% 5324
2022
Q3 		$985K Buy
58,935
+20,103
+52% +$400K ﹤0.01% 4892
2022
Q2 		$544K Buy
38,832
+26,016
+203% +$351K ﹤0.01% 5372
2022
Q1 		$207K Sell
12,816
-488
-4% -$7.47K ﹤0.01% 5906
2021
Q4 		$285K Buy
13,304
+5,900
+80% +$101K ﹤0.01% 5873
2021
Q3 		$108K Buy
7,404
+6,757
+1,044% +$112K ﹤0.01% 6320
2021
Q2 		$13K Buy
+647
New +$16.3K ﹤0.01% 7149

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley's DSGN Position: Q1 2026 in Review

Morgan Stanley reduced its Design Therapeutics (DSGN) stake by 6.5% in Q1 2026, selling an estimated $463K and leaving 656,565 shares worth $6.99M. The position accounts for ﹤0.01% of the portfolio, ranked #3871.

Morgan Stanley first reported a position in DSGN in Q2 2021 and has held it in 20 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Morgan Stanley held 656,565 shares of Design Therapeutics worth $6.99M as of Q1 2026.
  • Morgan Stanley sold 45,741 Design Therapeutics shares in Q1 2026, an estimated $463K.
  • Design Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3871 holding.
  • Morgan Stanley first reported a position in Design Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.